{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:41:17Z","timestamp":1792636877529,"version":"4.5.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020124","name":"Seagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Cisplatin-based chemotherapy has been the standard of care for patients with locally advanced or metastatic urothelial cancer (la\/mUC). Enfortumab vedotin, an antibody-drug conjugate directed to Nectin-4, and pembrolizumab, an immune checkpoint inhibitor, are two therapies that have individually provided a survival benefit in patients with la\/mUC. The combination regimen of enfortumab vedotin plus pembrolizumab was evaluated in EV-302 (KEYNOTE-A39; NCT0422385), a phase 3 study that showed statistically significant and clinically meaningful improvement in overall survival, progression-free survival, and a key secondary endpoint of overall response rate versus chemotherapy. Based on these results and those from the EV-103 (KEYNOTE-869; NCT03288545) Dose Escalation cohort, Cohort A, and Cohort K, enfortumab vedotin plus pembrolizumab was granted approval from the US Food and Drug Administration for the treatment of adults with la\/mUC. While guidelines and recommendations for the management of adverse events (AEs) have been developed for immune checkpoint inhibitor monotherapy and enfortumab vedotin monotherapy, additional guidance is needed for managing AEs that occur with enfortumab vedotin plus pembrolizumab. As monotherapies, enfortumab vedotin and pembrolizumab are both associated with some of the AEs observed with the combination, such as skin reactions, pneumonitis, and diarrhea, which may confound the attribution of the AE to a specific agent and thereby complicate clinical management. In this manuscript, we aim to provide recommendations for best practice for patient care and the management of AEs of clinical interest for patients with la\/mUC receiving enfortumab vedotin plus pembrolizumab, including skin reactions, peripheral neuropathy, hyperglycemia, and pneumonitis. These recommendations were developed based on published guidelines, expert opinions, and the clinical experience of the authors, which include oncologist, advanced practice provider, nursing, and pharmacy perspectives. In addition, guidance on patient education and communication is provided. With vigilant monitoring, early detection, and prompt intervention of treatment-emergent AEs based on recommended approaches described herein, it is the authors\u2019 experience that most AEs can be managed with supportive therapy and dose modification\/interruptions, allowing patients to continue treatment.<\/jats:p>","DOI":"10.3389\/fonc.2024.1326715","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T11:22:00Z","timestamp":1713784920000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer"],"prefix":"10.3389","volume":"14","author":[{"given":"Blaine","family":"Brower","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asia","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Eitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Alex","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Rembisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew I.","family":"Milowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-019-02984-4","article-title":"The global burden of urinary bladder cancer: an update","volume":"38","author":"Richters","year":"2020","journal-title":"World J Urol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/s41598-018-19199-z","article-title":"The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection","volume":"8","author":"Wong","year":"2018","journal-title":"Sci Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.09.191","article-title":"PCN108 - targeted literature review of the burden of illness in urothelial carcinoma","volume":"21","author":"Shah","year":"2018","journal-title":"Value Health"},{"key":"B5","unstructured":"SEER Cancer Stat Facts: Bladder Cancer2024"},{"key":"B6","doi-asserted-by":"publisher","first-page":"102072","DOI":"10.1016\/j.ctrv.2020.102072","article-title":"Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options","volume":"89","author":"Koufopoulou","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B7","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer2024"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.03.012","article-title":"Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced\/metastatic urothelial carcinoma by cisplatin-eligibility","volume":"41","author":"Morgans","year":"2023","journal-title":"Urol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.euf.2021.08.009","article-title":"Overall survival of patients receiving cisplatin or carboplatin for primary metastatic urothelial carcinoma of the bladder: A contemporary Dutch nationwide cohort study","volume":"8","author":"Richters","year":"2022","journal-title":"Eur Urol Focus"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad174","article-title":"Clinical and economic outcomes in patients with metastatic urothelial carcinoma receiving first-line systemic treatment (the IMPACT UC I Study)","volume":"28","author":"Bilen","year":"2023","journal-title":"Oncologist"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.08.033","article-title":"Vinflunine\/gemcitabine versus carboplatin\/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)","volume":"127","author":"Holmsten","year":"2020","journal-title":"Eur J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"B15","volume-title":"Real-world avelumab maintenance eligibility and treatment patterns in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma","author":"Morgans","year":"2023"},{"key":"B16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/OTT","article-title":"PD1\/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer","volume":"11","author":"Stenehjem","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV\u2212201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"B22","unstructured":"PADCEV (enfortumab vedotin-ejfv) for injection2023"},{"key":"B23","unstructured":"KEYTRUDA (pembrolizumab) injection2024"},{"key":"B24","article-title":"1187 Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors","volume":"10","author":"Olson","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O'Donnell","year":"2023","journal-title":"J Clin Oncol"},{"key":"B27","volume-title":"Study EV-103 dose escalation\/cohort a: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1l) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la\/mUC) with nearly 4 years of follow-up","author":"Gupta","year":"2023"},{"key":"B28","unstructured":"FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer2023"},{"key":"B29","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Management of Immunotherapy-Related Toxicities2023"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1188\/21.CJON.E1-E9","article-title":"Enfortumab vedotin: Nursing perspectives on the management of adverse events in patients with locally advanced or metastatic urothelial carcinoma","volume":"25","author":"Pace","year":"2021","journal-title":"Clin J Oncol Nurs"},{"key":"B35","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE)2010"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.01.028","article-title":"Adverse events of immune checkpoint inhibitors therapy for urologic cancer patients in clinical trials: A collaborative systematic review and meta-analysis","volume":"81","author":"Wu","year":"2022","journal-title":"Eur Urol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8040575","article-title":"Management of the adverse effects of immune checkpoint inhibitors","volume":"8","author":"Morgado","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00738-6","article-title":"Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: A clinical perspective from pharmacovigilance","volume":"15","author":"Raschi","year":"2020","journal-title":"Target Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1111\/jdv.19454","article-title":"Skin toxicity of enfortumab vedotin: Proposal of a specific management algorithm","volume":"38","author":"Ingen-Housz-Oro","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B43","volume-title":"Patient-reported outcomes in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer treated with enfortumabvedotinalone or in combination with pembrolizumab in the Phase 1b\/2 EV-103 Cohort K study","author":"Milowsky","year":"2023"},{"key":"B44","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Cancer-Related Fatigue2023"},{"key":"B45","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","article-title":"Cancer-related fatigue\u2013mechanisms, risk factors, and treatments","volume":"11","author":"Bower","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-009-1056-z","article-title":"Cancer-related fatigue: the approach and treatment","author":"Escalante","year":"2009","journal-title":"J Gen Intern Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.02.016","article-title":"Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment","volume":"31","author":"Fabi","year":"2020","journal-title":"Ann Oncol"},{"key":"B48","unstructured":"Managing your care2023"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1326715\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T11:22:09Z","timestamp":1713784929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1326715\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":48,"alternative-id":["10.3389\/fonc.2024.1326715"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1326715","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,22]]},"article-number":"1326715"}}